Effect of splenectomy on T-cell subsets and plasma HIV viral titers in HIV-infected patients

Journal of Human Virology

Volumn 1, Issue 5, 1998, Pages 338-345

  Bernard, Nicole F ^a,c   Chernoff, David N ^b   Tsoukas, Christos M ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b NOVARTIS PHARMA AG   (Switzerland)

^c MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

AIDS; HIV; Plasma viral titer; Splenectomy; T lymphocyte subsets

Indexed keywords

VIRUS RNA;

ADULT; ARTICLE; BLOOD; COMPARATIVE STUDY; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOLOGY; ISOLATION AND PURIFICATION; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MIDDLE AGED; SPLENECTOMY; T LYMPHOCYTE SUBPOPULATION; VIROLOGY; VIRUS LOAD;

ADULT; DISEASE PROGRESSION; HIV; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; LYMPHOCYTE COUNT; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RNA, VIRAL; SPLENECTOMY; T-LYMPHOCYTE SUBSETS; VIRAL LOAD;

EID: 0032107319     PISSN: 10909508     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-358.
2. Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner-Racz K, Haase AT. Massive covert infection of helper T Lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993;362:359-362.
3. Oksenhendler E, Seligmann M. HIV-related thrombocytopenia. Immunodefic Rev 1990; 2:221-231.
4. Oksenhendler E, Bierling P, Chevret S, et al. Splenectomy is safe and effective in human immunodeficiency virus-related immune thrombocytopenia. Blood 1993;82:29-32.
5. Morlat P, Dequae-Merchadou L, Dabis F, Chene G, Salamon R, Beylot J, and the Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA). Splenectomy and prognosis in HIV infection. AIDS 1996;10:172-194.
6. Tsoukas CM, Bernard NF, Abrahamovicz M, et al. Effect of splenectomy on slowing HIV disease progression. Arch Surg 1998;133:25-21.
7. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morbid Mortal Weekly Rep 1987;36:1S-15S.
8. Mellors JW, Rinaldo CRJr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167.
9. Coyle T, Cynamon M, Blair D, Poiesz BJ. Changes in the lymphocyte count and lymphocyte subsets after splenectomy in human immunodeficiency virus infection [letter]. Am J Hematol 1992;41:144-146.
10. Tunkel AR, Kelsall B, Rein MF, et al. Case report: increase in CD4 lymphocyte counts after splenectomy in HIV-infected patients. Am J Med Sci 1993;306:105-110.
11. Mientjes GH, Miedema F, van den Hoek JA, Coutinho RA. Immunologic alterations in splenectomized HIV-infected intravenous drug users [letter]. AIDS 1994;8:269-271.
12. Fairley CK, Spelman D, Street A, Jennens ID, Spicer WJ, Crowe S. CD4 lymphocyte numbers after splenectomy in patients infected with the human immunodeficiency virus. Int J STD AIDS 1994;5:177-181.
13. Zurlo JJ, Wood L, Caglione MM, Polis MA. Effect of splenectomy on T lymphocyte subsets in patients infected with the human immunodeficiency virus. Clin Infect Dis 1995;20:768-771.
14. Structure and Function of the Spleen. In Williams WJ, Beutler E, Erslev AJ, Lichtman MA. Hematology, 4th ed. New York: McGraw-Hill, 1990.
15. + lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986;321:1563-1566.
16. + T cells. Science 1995;270:1811-1815.
17. + T-cell-mediated suppression of HIV-1 long terminal repeat-driven gene expression is not modulated by the CC chemokines RANTES, macrophage inflammatory protein (MIP)-1α and MIP-1β. AIDS 1997; 11:575-580.
18. Lafeuillade A, Poggi C, Tamalet C, et al. HIV-1 viraemia and splenectomy [letter]. AIDS 1995;9:821-822.
19. Henry K, Dailey P, Erice A, Posalary Z, Melroe H. Effect of splenectomy on the level of HIV RNA in plasma and PBLs as determined by the quantiplex HIV RNA assay. Presented at the Second National Conference on Retroviruses and Related Infections, Washington, DC, 1995.
20. Joag SV, Stephens EB, Adams RJ, Foresman L, Narayan O. Pathogenesis of SIVmac infection in Chinese and Indian rhesus macaques: effects of splenectomy on virus burden. Virology 1994;200:436-446.
21. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-739.
22. Decks SG, Coleman RL, White R, et al. Variance of plasma human immunodeficiency virus type 1 RNA levels measured by branched DNA within and between days. J Infect Dis 1997;176:514-517.
23. Raboud JM, Montaner JS, Conway B, et al. Variation in plasma RNA levels, CD4 cell counts, and p24 antigen levels in clinically stable men with human immunodeficiency virus infection. J Infect Dis 1996;174:191-194.
24. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less (AIDS Clinical Trials Group 320 Study Team). N Engl J Med 1997; 337:725-733.
25. Graham NM, Hoover DR, Park LP, et al. Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Ann Intent Med 1996;124:1031-1038.
26. Marschner IC, Collier AC, Coombs RW, et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998;177:40-47.
27. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335: 1081-1090.
28. Katzenstein DA, Hammer SM, Hughes MD et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1091-1108.